slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 77,461-77,490
Pages 3,679
Rows per page 30
Component
77,461-77,490 of 110,355
31
The slide uses a structural layout to map platform capabilities to specific therapeutic products.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
The slide uses a step-diagram to illustrate dose escalation.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
Includes a process diagram illustrating the medical procedure and a list of key attributes.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
34
Includes a comparative table of clinical outcomes (ORR, CR/sCR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The slide highlights safety data (CRS and ICANS) and toxicity management interventions.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
NXC-201 is highlighted with an orange border to emphasize its specific regimen.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
38
The table compares clinical trial inclusion criteria across four different therapies for relapsed/refractory multiple myeloma.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
39
Highlights NXC-201's competitive advantage regarding prior BCMA therapy exclusion.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
The slide uses a numbered process flow layout.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
41
The slide uses cross-trial comparison; disclaimer notes these are not head-to-head results.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
42
Includes a scientific mechanism of action diagram at the bottom.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
43
The slide uses a segmented horizontal axis to compare two distinct market segments by revenue.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
54
The slide uses a combination of mechanism diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
07
The slide uses a hierarchical structure to map Kakao's business units. The data points represent ownership percentages and valuation in trillion KRW.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations Beat · ProblemLoop · Logic Chain1 hit
15
The slide highlights the integration of various commerce services under the Kakao platform.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations Beat · SolutionLoop · Logic Chain1 hit
16
Uses concentric circles to represent market segments (Total -> Online -> Kakao).Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations Beat · SolutionLoop · Logic Chain1 hit
17
The slide highlights four pillars: Kakao T (general), Taxi (branded), MyCar (vehicle management), and Parking.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations Beat · SolutionLoop · Logic Chain1 hit
28
The slide displays stacked bar charts for two main business divisions, showing percentage contributions of sub-segments and total quarterly revenue figures.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations Beat · Financials1 hit
29
Data presented in stacked bar charts comparing FY22 and FY23 performance.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations Beat · Financials1 hit
36
The table includes YoY and QoQ growth metrics for various expense categories, with a footnote explaining accounting changes related to SM Entertainment.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations Beat · Financials1 hit
43
The slide compares headcount (left) and CapEx (right) over five quarters from 4Q22 to 4Q23.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations 1 hit
44
Contains quarterly income statement data (4Q22-4Q23) and annual balance sheet data (2021-2023).Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations 1 hit
48
The Korean text '감사합니다' translates to 'Thank you'.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations 1 hit
13
Focuses on the EPA Clean School Bus Program and state-level legislative momentum.Lion Electric | Investor Presentation Deck | 32 slides · Lion Electric
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
04
The slide uses a Venn-like diagram to show the relationship between the specific TAM segments and the broader global market.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Humble OriginsLoop · Logic Chain1 hit
07
The slide uses a before/after visual comparison of the part structure alongside a bar chart for performance validation.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
19
Includes a footnote explaining the composition of non-recurring costs for both years.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
20
Includes footnote detailing non-recurring costs.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
03
The slide uses a process-flow structure to connect the technology (LNCs) to current clinical validation (MAT2203) and future pipeline expansion.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
14
The slide highlights the limitations of current first-line azole treatments and identifies a specific patient sub-segment with high unmet need.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit